Agios Presents Positive Results from Phase 2 Portion of the

– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo –

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , United States , San Diego , California , Texas , Houston , American , Modupe Idowu , Dan Budwick , Sarah Gheuens , Chris Taylor , Mcgovern Medical School , Gut Health , Agios Pharmaceuticals Inc , Exchange Commission , American Society Of Hematology , Corporate Communications , Agios Pharmaceuticals , European Union , Nasdaq , Ut Physicians Comprehensive Sickle Cell Center , Hemoglobin Response Compared , Improvements Observed , Annualized Rates , Sickle Cell Pain Crises , Participants Treated , Ghost Live , Webcast Investor Event , American Society , Annual Meeting , Texas Health Science Center , Comprehensive Sickle Cell Center , Multicenter Study , Patients With Sickle Cell Disease , Abstract Session , Cell Disease , Sickle Cell Trait , Excluding Thalassemias , Disease Modifying Therapeutics , Sickle Cell , Substrates Including Hormonal Contraceptives , Prescribing Information , Product Characteristics , Private Securities Litigation Reform Act , Region ,